A new module in the drug development process: preclinical multi-center randomized controlled trial of R-ketamine on alcohol relapse.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology May 1, 2025 Marcus W. Meinhardt, Ivan Skorodumov, Jérôme Jeanblanc et al. 8 citations
The drug development process in psychiatry faces significant challenges due to low reproducibility rates in animal testing, which often leads to translation failures. To address this issue, we introduce a new approach in psychiatric drug development: a preclinical randomized controlled trial (preRCT). To demonstrate its potential utility, we conducted a multi-center preRCT using the alcohol...